ORAGENICS INC

Listed Company

OGENCIK 0001174940NYSENon-AcceleratedSmaller ReportingPharmaceutical PreparationsFloridaFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-9.80M

Total Assets

$10.07M

Equity

$8.28M

Shares Out

4.34M

Op. Cash Flow

$-9.20M

Business

ORAGENICS INC develops intranasal pharmaceutical therapies focused on neurology and infectious disease, centering on a nasal drug delivery platform. Its main product candidate is ONP-002, a synthetic lipophilic neurosteroid formulated as a spray-dried powder delivered via a breath-powered intranasal device for treatment of mild traumatic brain injury (concussion). Key business activities include development and commercialization of drug‑device combination products, management of related intellectual property, and clinical development under its Neurology Assets segment. It conducts clinical trials in Australia, plans U.S. regulatory filings, and seeks distribution or licensing partners internationally.

Summary from filing dated 2025-03-14

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	2	4	15	10	11
General and administrative	7	6	5	4	5
Total operating expenses	9	11	21	15	16
Loss from operations	−9	−11	−21	−14	−16
Interest income	182,229	45,897	210,394	135,900	75,847
Interest expense	−785,930	−29,828	−30,591	—	—
Foreign currency exchange, net	−13,193	−25,172	—	—	—
Total other income (expense), net	−616,894	−9,103	249,166	132,379	59,404
Loss before income taxes	−10	−11	−21	−14	−16
Income tax benefit	137,000	—	—	—	—
Net loss	−10	−11	−21	−14	−16
Basic net loss per share	−4.56	−47.88	−9.18	−7.11	−8.09
Diluted net loss per share	−4.56	−47.88	−9.18	−7.11	—
Weight average shares outstanding, basic	2	220,731	2	2	2
Weight average shares outstanding, diluted	2	220,731	2	2	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	4	864,840	3	11	27
Short-term investments	4	—	—	—	—
Interest receivable	53,082	—	—	—	—
Prepaid expenses and other current assets	2	607,670	382,273	3	434,699
Total current assets	10	1	4	14	28
Total assets	10	1	5	15	28
Accounts payable and accrued expenses	2	1	1	1	947,574
Short-term notes payable, net of debt issuance costs	227,348	328,528	312,703	267,640	303,416
Total liabilities	2	2	2	—	—
Preferred stock, no par value; 50,000,000 shares authorized; 429,291 Series H and 7,488,692 Series F outstanding at December 31, 2025, and 0 Series H and 7,488,692 Series F outstanding at December 31, 2024.	—	—	2	2	3
Common stock, $0.001 par value; 350,000,000 shares authorized; 4,271,529 and 419,003 shares issued and outstanding at December 31, 2025, and December 31, 2024, respectively	4,271	419	3,081	2,025	2,003
Additional paid-in capital	235	217	208	197	195
Accumulated deficit	−227	−217	−206	−186	−171
Total stockholders equity (deficit)	8	−211,885	3	13	26
Total liabilities and stockholders equity (deficit)	10	1	5	15	28

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Amortization of debt discount and closing costs	771,437	—	—	—	—
Stock-based compensation expense	642,364	516,049	1	742,203	2
Stock-based compensation recapture expense	−86,617	—	—	—	—
Common stock for services rendered	126,140	—	—	—	—
Other receivables	−53,082	—	—	6,987	−6,987
Prepaid expenses and other current assets	−1	2	2	−2	508,576
Operating lease right of use assets	—	9,811	337,629	—	—
Accounts payable and accrued expenses	203,144	−119,800	25,798	176,625	10,554
Change in operating lease liabilities	—	−9,811	−347,075	—	—
Net cash used in operating activities	−9	−9	−7	−15	−13
Borrowings on short-term notes payable	2	—	—	—	—
Payments on short-term notes payable	−3	−693,109	−566,046	−564,205	−524,980
Net proceeds from issuance of preferred stock and warrants	15	—	—	—	—
Net proceeds from issuance of common stock	3	7	—	69,289	27
Net cash provided by financing activities	17	6	283,880	−494,916	23
Net increase (decrease) in cash and cash equivalents	8	−3	−8	−16	10
Interest paid	22,353	29,828	30,591	9,290	15,756

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro